Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled, Multi-region Study to Evaluate the Efficacy, Safety, and Immunogenicity of Inactivated EV71 Vaccine Produced in Vero Cells With Adjuvant in Infants and Children

NCT03865238 is registered in ClinicalTrials.gov with Medigen Vaccine Biologics Corp. as lead sponsor.

NCT NCT03865238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03865238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled, Multi-region Study to Evaluate the Efficacy, Safety, and Immunogenicity of Inactivated EV71 Vaccine Produced in Vero Cells With Adjuvant in Infants and Children
Lead sponsor
Medigen Vaccine Biologics Corp.
Phase
Phase 3
Overall status
Completed
Start date
April 23, 2019
Completion date
April 16, 2021
Enrollment
3,061 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

enterovirus 71 infection